ArticleEuropean thyroid journal2026
Thyroid hormone therapy in a population cohort over two decades indicates persistent overtreatment.
Article in European thyroid journal, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: Thyroid hormones (THs) are among the most prescribed medications worldwide, and regular monitoring of thyroid function is required to ensure optimal management. Both over- and undertreatment with THs is associated with health risks, including increased cardiovascular morbidity and mortality, as well as higher socioeconomic costs. We investigated how changes in treatment concepts and guideline recommendations over two decades have influenced the frequency and quality of TH treatment in a high-income country. Methods: Data from 7,711 participants in the German population-based Heinz Nixdorf Recall (HNR) study were descriptively analyzed to assess the prevalence of reported thyroid disease, TH therapy, and thyrotropin (TSH) concentrations measured by immunoassay over the period 2000-2023. The mean age differed from 53.8 ± 15.1 years to 68.7 ± 7.3 years (45.8-49.6% males). Descriptive analyses were also stratified by age, sex, and educational attainment. Results: The prevalence of reported thyroid disease remained stable throughout the study period, whereas TH prescription increased from 9.2 to 15.3% over two decades. TH therapy was more common among women and older participants. Compared with individuals without thyroid disease or those with thyroid disease not treated with THs, median TSH concentrations were lower in participants receiving TH therapy, with the greatest reduction observed in older individuals. At study baseline, 35% of participants with TSH concentrations <0.45 mIU/L reported TH treatment, and this proportion remained high (25%) during the 20-year follow-up. Conclusion: TH therapy in the study population increased over the past two decades. TSH measurements revealed persistent overtreatment, particularly among older individuals. These findings highlight a concerning gap between updated guideline recommendations for TH therapy and its implementation in routine clinical practice. Greater emphasis is needed on translating scientific evidence into patient care through improved education of both physicians and patients, promoting a more restrictive approach to thyroid function testing, TH therapy, regular review of ongoing TH treatment, and age-adjusted TH dosing.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.